GleamWall
中文EN

CLDX Celldex Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 744218 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.9%
TTM net income YoY-37.6%
TTM EPS YoY-26.9%
Revenue 3-yr CAGR-66.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-211,684.8%
Net margin-195,608.9%
FCF margin-164,391.8%
EBITDA margin-209,321.5%

Returns

ROE-49.5%
ROA-45.1%
ROIC (approx.)-44.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue4,915.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$22,000$15,000$121,000$0$730,000$695,000$1.18M
R&D expense$67.41M$67.54M$73.00M$75.33M$62.93M$54.20M$52.61M$46.94M
SG&A expense$14.84M$13.10M$11.45M$11.94M$10.69M$10.39M$10.82M$10.26M
Operating income-$82.25M-$80.62M-$84.44M-$87.15M-$73.62M-$63.86M-$62.74M-$56.03M
Net income-$75.56M-$73.50M-$78.69M-$81.32M-$67.04M-$56.60M-$53.80M-$47.09M
EBITDA-$81.09M-$79.72M-$83.58M-$86.34M-$72.79M-$62.98M-$61.87M-$55.21M
EPS (basic)-0.96-0.94-1.18—-1.01-0.85-0.81—
EPS (diluted)-0.96-0.94-1.18—-1.01-0.85-0.81—
Weighted avg. shares (diluted)78.53M77.84M66.57M—66.42M66.39M66.38M—
Balance sheet
Cash & equivalents$26.95M$47.45M$35.73M$28.87M$36.04M$23.04M$17.14M$28.36M
Short-term investments$623.37M$670.13M$415.73M$489.70M$547.19M$607.29M$656.15M$696.92M
Current assets$663.74M$724.93M$459.22M$534.66M$604.34M$648.40M$693.76M$747.16M
PP&E, net$11.00M$9.76M$7.40M$5.33M$4.83M$4.39M$4.60M$4.35M
Intangibles$27.19M$27.19M$27.19M$27.19M$27.19M$27.19M$27.19M$27.19M
Total assets$721.53M$782.35M$511.25M$582.98M$648.44M$692.41M$739.47M$792.34M
Current liabilities$60.52M$61.33M$51.47M$50.99M$46.47M$32.96M$32.02M$39.50M
Total liabilities$72.06M$67.78M$55.03M$55.82M$50.08M$37.00M$36.49M$45.34M
Shareholders' equity$649.47M$714.56M$456.23M$527.16M$598.36M$655.41M$702.98M$747.00M
Shares outstanding78.53M78.50M66.57M66.55M66.45M66.39M66.38M66.37M
Cash flow statement
Operating cash flow-$65.03M-$57.41M-$65.59M-$63.94M-$48.63M-$44.01M-$54.37M-$32.48M
Capital expenditure$1.67M$3.18M$1.64M$1.28M$440,000$728,000$265,000$756,000
Free cash flow-$66.70M-$60.59M-$67.23M-$65.22M-$49.07M-$44.73M-$54.64M-$33.23M
Investing cash flow$43.42M-$255.52M$72.12M$55.42M$60.85M$49.85M$42.95M$24.05M
Financing cash flow$1.11M$324.66M$327,000$1.35M$774,000$63,000$202,000$386,000
Depreciation & amortization$1.16M$902,000$854,000$816,000$824,000$873,000$867,000$819,000
Stock-based compensation$10.97M$8.41M$8.52M$8.91M$8.80M$9.19M$9.32M$9.78M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.